Dr Sonia Yip

Oncology Translational Research Fellow
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5345
Fax +61 2 9562 5094

Map

Selected grants

2014

  • The Sydney Cancer Conference 2014 Bridging Research and Practice - Ian Potter Foundation Conference grant; Yip S, Reid G; Ian Potter Foundation/Travel Support.
  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Shannon C, Martyn J, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2013

  • Biobanking Stakeholder Network (BSN) Pre-Operative Consent Project; Yip S, Hawkins N, Miller D, Horvath L, Kench J, Brown S; Cancer Institute New South Wales/Community of Practice.
  • The biological basis of success or failure to the anti-VEGF agent, bevacizumab in patients with recurrent glioblastoma; Simes R, McDonald K, Brown C, Yip S; Cancer Council New South Wales/Research Project Grants.

2012

  • Personalising care in resectable pancreas cancer. GAP-T: a study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery.; Barbour A, Goldstein D, Goldstein D, Kench J, Yip S, Brown C, Hicks R, Chang D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR); Goldstein D, Brown C, Yip S, Barbour A; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Karapetis, C., Cheong, K., Yip, D., Strickland, A., Steer, C., Marx, G., Yip, S., Chrystal, K., Harper, P. (2010). A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 6(4), 289-305. [More Information]

Conferences

  • Yip, S. (2011). Translational research and personalised medicine. The Australian New Zealand Gynaecological Oncology Group (ANZGOG) ASM.

2011

  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Yip, S. (2011). Translational research and personalised medicine. The Australian New Zealand Gynaecological Oncology Group (ANZGOG) ASM.

2010

  • Karapetis, C., Cheong, K., Yip, D., Strickland, A., Steer, C., Marx, G., Yip, S., Chrystal, K., Harper, P. (2010). A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 6(4), 289-305. [More Information]

To update your profile click here. For support on your academic profile contact .